Western Standard LLC Takes $5.04 Million Position in AngioDynamics, Inc. $ANGO

Western Standard LLC purchased a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the 2nd quarter, Holdings Channel reports. The fund purchased 387,188 shares of the medical instruments supplier’s stock, valued at approximately $5,037,000. AngioDynamics comprises about 1.7% of Western Standard LLC’s holdings, making the stock its 17th largest position.

A number of other large investors have also modified their holdings of ANGO. Farther Finance Advisors LLC lifted its position in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in AngioDynamics in the 4th quarter worth about $27,000. State of Wyoming bought a new position in AngioDynamics in the 2nd quarter worth about $31,000. Russell Investments Group Ltd. increased its stake in shares of AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in shares of AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

Analyst Ratings Changes

ANGO has been the subject of several analyst reports. HC Wainwright boosted their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group raised their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Stock Up 1.6%

Shares of ANGO opened at $16.07 on Thursday. The firm has a 50-day moving average price of $13.81 and a 200 day moving average price of $11.99. The firm has a market capitalization of $664.17 million, a PE ratio of -18.47 and a beta of 0.33. AngioDynamics, Inc. has a 52-week low of $8.74 and a 52-week high of $16.29.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities analysts expect that AngioDynamics, Inc. will post -0.25 EPS for the current year.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.00% of the stock is owned by company insiders.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.